Marilena Vrana: Access, Resilience, and Policy Priorities Ahead of IPPC2026
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, reposted from on LinkedIn:
”A timely and important contribution from Nikolaj Siersbæk and Copenhagen Economics on the role of plasma-derived medicines in Europe.
This updated report builds on their 2021 analysis and reinforces a critical reality: about a million patients across the continent rely on these life-saving therapies, often with no alternative treatment options.
At the same time, it highlights growing structural challenges, including constrained plasma supply and Europe’s continued reliance on imports.
Addressing these issues will require forward-looking, tailored policy solutions, not a one-size-fits-all approach.
These themes go straight to the heart of what we’ll be discussing at IPPC2026.
I’m particularly looking forward to Nikolaj opening the Congress with a keynote that sets the stage for deeper conversations on Resilience Reach Responsibility, and to engaging with stakeholders across the plasma-PDMP ecosystem in this important conversation on strengthening patient access and resilience in healthcare.
Quoting Copenhagen Economics‘s post:
”The patient need for plasma-derived therapies is increasing.
This trend coincides with escalating concerns over the supply of plasma in the longer term, and a heavy reliance in Europe on plasma imports from the U.S.
We are proud to launch an update of our 2021 publication on the value of plasma-derived therapies in Europe.
We find that:
- The number of patients that can benefit from plasma-derived therapies is significant and some of these diseases have no alternative treatments to plasma-derived therapies
- The plasma-derived therapies industry supports the European economy both directly and through the cascading effects across the broader supply chain
- The plasma-derived therapies industry in Europe is constrained due to the scarcity of donated human plasma, and while some of the market issues surrounding the industry could be alleviated through more effective utilisation of plasma, a re-evaluation of donation schemes would be needed to secure the European plasma supply
Reach out to Nikolaj Siersbæk to hear more, and read the full report”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke